Bupranolol (BioDeep_00000033386)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol

化学式: C14H22ClNO2 (271.1338982)
中文名称: 布拉洛尔
谱图信息: 最多检出来源 Homo sapiens(blood) 5.26%

分子结构信息

SMILES: CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O
InChI: InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3

描述信息

Bupranolol is only found in individuals that have used or taken this drug. It is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol:http://www.drugbank.ca/drugs/DB00571. Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Bupranolol is an orally active, competitive and non-selective β-adrenoceptor antagonist without intrinsic sympathomimetic activity[1].

同义名列表

9 个代谢物同义名

1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol; Desma brand OF bupranolol hydrochloride; BUPRANOLOL hydrochloride; Bupranololum; Betadrenol; Bupranolol; BUPRANOL; KL-255; b 1312



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • E Pujos, C Cren-Olivé, O Paisse, M M Flament-Waton, M F Grenier-Loustalot. Comparison of the analysis of beta-blockers by different techniques. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Dec; 877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. [PMID: 19879818]
  • Faiyaz Shakeel, Sanjula Baboota, Alka Ahuja, Javed Ali, Sheikh Shafiq. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. Journal of nanobiotechnology. 2008 Jul; 6(?):8. doi: 10.1186/1477-3155-6-8. [PMID: 18613981]
  • Mei-xia Li, Xiao-liang Wang, Jia-ning Tang, Xiao-jun Liu, Jue Tian, Li Yan, Hui-rong Liu. [Distribution and property of anti-beta3-adrenoceptor autoantibody in patients with heart failure]. Zhonghua xin xue guan bing za zhi. 2005 Dec; 33(12):1114-8. doi: NULL. [PMID: 16563283]
  • Hans H Maurer, Oliver Tenberken, Carsten Kratzsch, Armin A Weber, Frank T Peters. Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. Journal of chromatography. A. 2004 Nov; 1058(1-2):169-81. doi: . [PMID: 15595665]
  • Katrin Hücking, Marianthe Hamilton-Wessler, Martin Ellmerer, Richard N Bergman. Burst-like control of lipolysis by the sympathetic nervous system in vivo. The Journal of clinical investigation. 2003 Jan; 111(2):257-64. doi: 10.1172/jci14466. [PMID: 12531882]
  • T Ogiso, T Hata, M Iwaki, T Tanino. Transdermal absorption of bupranolol in rabbit skin in vitro and in vivo. Biological & pharmaceutical bulletin. 2001 May; 24(5):588-91. doi: 10.1248/bpb.24.588. [PMID: 11379788]
  • N Atef, M Lafontan, A Doublé, C Hélary, A Ktorza, L Pénicaud. A specific beta 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. European journal of pharmacology. 1996 Mar; 298(3):287-92. doi: 10.1016/0014-2999(95)00802-0. [PMID: 8846828]
  • J Galitzky, M Reverte, C Carpene, M Lafontan, M Berlan. Beta 3-adrenoceptors in dog adipose tissue: studies on their involvement in the lipomobilizing effect of catecholamines. The Journal of pharmacology and experimental therapeutics. 1993 Jul; 266(1):358-66. doi: NULL. [PMID: 8101220]
  • J Peleska, A Jindra, M Jáchymová, J Zvárová, J Savliková, M Jarolim. Humoral changes during a long-term antihypertensive treatment. Agents and actions. Supplements. 1987; 22(?):191-6. doi: 10.1007/978-3-0348-9299-5_20. [PMID: 3324708]
  • J Nagler, H Dittrich. [Potassium-sparing effect of triamterene in a 3-component combination preparation for the therapy of hypertension]. Wiener klinische Wochenschrift. 1986 Jan; 98(2):49-53. doi: NULL. [PMID: 3962310]
  • A Wellstein, H Küppers, H F Pitschner, D Palm. Transdermal delivery of bupranolol: pharmacodynamics and beta-adrenoceptor occupancy. European journal of clinical pharmacology. 1986; 31(4):419-22. doi: 10.1007/bf00613517. [PMID: 3028816]
  • S Mantelli, P Speiser, H Hauser. Phase behaviour of a diglyceride prodrug: spontaneous formation of unilamellar vesicles. Chemistry and physics of lipids. 1985 Aug; 37(4):329-43. doi: 10.1016/0009-3084(85)90087-8. [PMID: 2996795]
  • G Tutsch, G Guberner, R Nitsch-Fitz, H Rheindorf, K T Ziegler, G Hitzenberger. [Treatment of medium-severe essential hypertension with beta-Aldopur under practice conditions]. Wiener medizinische Wochenschrift. Supplement. 1985; 89(?):215-21. doi: NULL. [PMID: 3859956]
  • L M Walmsley, R R Brodie, L F Chasseaud. Determination of carboxybupranolol, the major metabolite of bupranolol, in human plasma by high-performance liquid chromatography. Journal of chromatography. 1984 Nov; 311(1):227-33. doi: 10.1016/s0378-4347(00)84715-5. [PMID: 6151568]
  • H Winkler, B Lemmer. Determination of the beta-adrenoceptor blocking drug bupranolol in plasma and tissues of the rat by high-performance liquid chromatography with ultraviolet detection. Journal of chromatography. 1984 Jul; 309(1):193-7. doi: 10.1016/0378-4347(84)80024-9. [PMID: 6480767]
  • A Schnabel, W Kindermann, V Steinkraus, O Salas-Fraire, G Biro. Metabolic and hormonal responses to exhaustive supramaximal running with and without beta-adrenergic blockade. European journal of applied physiology and occupational physiology. 1984; 52(2):214-8. doi: 10.1007/bf00433395. [PMID: 6143664]
  • A Beck, W Conca, S Bacher, G Raberger. Plasma insulin levels and beta-adrenoceptor antagonists. Relevance of the steric configuration of beta-adrenoceptor antagonists to their effect on glucose tolerance. Naunyn-Schmiedeberg's archives of pharmacology. 1983 Sep; 324(1):46-9. doi: 10.1007/bf00647837. [PMID: 6138714]
  • A Schrey, H Hartmann, G A Jutzler, R Grund, H T Forst. [Treatment of hypertension in mild kidney insufficiency]. Therapie der Gegenwart. 1982 Aug; 121(8):465-75. doi: NULL. [PMID: 6753222]
  • A R Waller, L F Chasseaud, R Bonn, T Taylor, A Darragh, R Girkin, W H Down, E Doyle. Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys. Drug metabolism and disposition: the biological fate of chemicals. 1982 Jan; 10(1):51-4. doi: NULL. [PMID: 6124383]
  • C Diehm, H Mörl, U Müller-Bühl, A Schrey, R Grund. [Ambulant treatment of hypertension with cardiotensin (author's transl)]. MMW, Munchener medizinische Wochenschrift. 1981 Sep; 123(39):1458-62. doi: NULL. [PMID: 6792535]
  • H J Liewald, A Schrey, R Grund. [Low diuretic dosage in a beta blocker-diuretic combination]. Medizinische Klinik. 1980 Aug; 75(18):654-7. doi: NULL. [PMID: 6106884]
  • E Hayashi, T Maeda, R Hasegawa, T Tomita. The effect of myo-inositol deficiency on lipid metabolism in rats. III. The mechanism of an enhancement in lipolysis due to myo-inositol deficiency in rats. Biochimica et biophysica acta. 1978 Nov; 531(2):197-205. doi: 10.1016/0005-2760(78)90143-1. [PMID: 214137]
  • Z Albert, A Szewczuk, W Albert. Effect of passages of Morris hepatoma 5123D in F1 (Buffalo X Wistar) rats on permanent decrease of gamma-glutamyltranspeptidase activity. Neoplasma. 1977; 24(1):49-55. doi: NULL. [PMID: 14309]